Mohammed, A., Miller, M. S., Lubet, R. A., Suen, C. S., Sei, S., Shoemaker, R. H., . . . Grubbs, C. J. (2019). Combination of erlotinib and naproxen employing pulsatile or intermittent dosing profoundly inhibits urinary bladder cancers. Cancer Prev Res (Phila).

Mohammed, Altaf, Mark Steven Miller, Ronald A. Lubet, Chen S. Suen, Shizuko Sei, Robert H. Shoemaker, Margaret M. Juliana, Fariba L. Moeinpour, und Clinton J. Grubbs. "Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers." Cancer Prev Res (Phila) 2019.

Mohammed, Altaf, et al. "Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers." Cancer Prev Res (Phila) 2019.